AQST (Aquestive Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Aquestive Therapeutics, Inc. Common Stock (AQST) is a publicly traded Healthcare sector company. As of May 21, 2026, AQST trades at $4.17 with a market cap of $518.74M and a P/E ratio of -6.70. AQST moved +2.20% today. Year to date, AQST is -33.07%; over the trailing twelve months it is +74.48%. Its 52-week range spans $2.12 to $7.55. Analyst consensus is strong buy with an average price target of $8.75. Rallies surfaces AQST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns AQST stock?
Hedge funds tracked by Rallies that own AQST include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aquestive Therapeutics, Inc. Common Stock.
AQST Key Metrics
Key financial metrics for AQST
Metric
Value
Price
$4.17
Market Cap
$518.74M
P/E Ratio
-6.70
EPS
$-0.62
Dividend Yield
0.00%
52-Week High
$7.55
52-Week Low
$2.12
Volume
167
Avg Volume
0
Revenue (TTM)
$50.27M
Net Income
$-68.91M
Gross Margin
63.45%
Top Hedge Funds Holding AQST
Exoduspoint Capital holds 38.10K shares of AQST, changed -79.86% as of Sep 30, 2025.
Hedge funds tracked by Rallies that own AQST include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aquestive Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for AQST?
Yes. Rallies tracks hedge fund and 13F ownership data for AQST, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AQST research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AQST. It does not provide personalized investment advice.
